A ternary association of KRas, EphA2 and integrins controls PDAC cell behaviour.

Authors

Mahak Fatima, Nasir Haider, Stuart A Cain, Bipul R Acharya, Megan R Chastney, Junzhe Zha, Matthew C Jones, Stacey Warwood, David Knight, Derek A O'Reilly, Jonathan D Humphries, Benjamin T Goult, Claus Jørgensen, Martin J Humphries

Published in

The Journal of biological chemistry. Pages 113421. Aug 10, 2026. Epub Aug 10, 2026.

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers, primarily because late detection, a lack of effective therapies and an abundant desmoplastic reaction result in elevated proliferation, invasion and immune evasion. KRas is the most frequently mutated driver gene in PDAC and, while drugs are now available that target this GTPase, there remains a need for further pharmacological options to treat the disease. As a first step to identify potential targets, this study aimed to define the molecular environment of KRas using proximity proteomics. A KRas^G12V-biotin ligase chimera was stably expressed in several PDAC cell lines and organoids, and associating proteins identified following biotin addition, streptavidin affinity isolation and mass spectrometry (MS). Among the 126 proteins that were specifically associated in all cell lines, five integrin subunits and the receptor tyrosine kinase ephrin type-A receptor 2 (EphA2) were consistently enriched. Both classes of receptor have been previously implicated in both Ras signalling and desmoplastic responses. A range of protein biochemical and microscopic analyses confirmed the spatial association of integrin β1 and EphA2 with KRas. Cellular KRas levels were reduced following depletion of both integrin β1 and EphA2, and depletion of EphA2 inhibited KRas-dependent migration. Taken together, these findings highlight a ternary crosstalk between receptor tyrosine kinase, integrin and KRas signalling, which provides insight into PDAC progression and signposts potential therapeutic vulnerabilities.

PMID:
42575445
Bibliographic data and abstract were imported from PubMed on 11 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.